BRISTOL-MYERS Aktie

 

Bristol Myers Squibb and Microsoft's new partnership aimed at accelerating early detection of lung cancer....

Bristol Myers Squibb and GSK stack up differently on growth, debt, pipelines and returns, making the stock-picking decision far from obvious...

Bristol Myers Squibb partners with Microsoft to use AI imaging tools to detect lung cancer earlier and support radiologists. read more...

BENGALURU, India, Jan. 20, 2026 /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement......

Der Einsatz von Künstlicher Intelligenz (KI) könnte die Diagnose von Krebs revolutionieren. Daran glaubt offenbar auch der Pharma-Konzern Bristol Myers Squibb. Die Amerikaner schließen sich mit keinem geringeren als den Software-Giganten Microsoft zusammen, um die Früherkennung von Lungenkrebs zu beschleunigen....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb Co. (BMY), on Tuesday announced that it has entered into an agreement with Microsoft Corp. (MSFT) to accelerate the early detection of lung cancer th......

US-Pharmariesen verlieren Patentschutz im Marktwert von Milliarden Dollar. Chinesische Biotechs liefern Ersatz. Was heißt das für den globalen Pharma-Markt?...

In the most recent trading session, Bristol Myers Squibb (BMY) closed at $55.26, indicating a -2.4% shift from the previous trading day....

NEW HAVEN, Conn.--(BUSINESS WIRE)--BioCT, Connecticut's life sciences trade organization, is pleased to announce the appointment of four distinguished executives to its Board of Directors. The organization has elected Ranjit Bindra, MD, PhD, Harvey and Kate Cushing Professor of Therapeutic Radiology and Professor of Pathology at Yale School of Medicine and serial bioscience entrepreneur; Angela Cacace, PhD, Chief Scientific Officer, Arvinas; Jennifer Good, Co-Founder, President, and Chief Executive Officer, Trevi Therapeutics; and Sydney Klein, Chief Information Security Officer and Head of Enterprise IT, Bristol Myers Squibb. Dr. Cacace will succeed former Board member John Houston, PhD, who is stepping down following his July 2025 announcement of plans to retire as President and Chief Executive Officer of Arvinas. Mr. Houston will continue his involvement with BioCT as a member of the organization's Emeritus Board, which is composed of distinguished former Board leaders who have made lasting contribut...

Bristol Myers Squibb Co. said about 5% of Opdivo patients are taking a new, easier-to-use version of the blockbuster cancer drug and said it's on course to meet the company's goal of adoption by at least 30% of patients in two years....

NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) reported positive topline data from the Phase 3 SCOUT-HCM trial, the first randomized, placebo-controlled study of a cardiac myosin inhibitor i......

Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...

Experienced leader in preclinical and clinical drug development will support expansion of Company's therapeutics pipeline for complex and common genetic diseasesCAMBRIDGE, England--(BUSINESS WIRE)--Enhanced Genomics ('Enhanced' or 'the Company'), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced Katerina Leftheris, Ph.D. has joined its Board of Directors. Katerina's appointment as a Director forms part of the Company's ongoing strategy to expand its internal therapeutics pipeline for drug targets identified using its 3D multi-omics platform. Katerina is an experienced scientific and executive leader, with over 30 years of experience in senior scientific positions in large pharma and biotech companies, including Bristol Myers Squibb (BMS), Celgene (acquired by BMS), and Pliant Therapeutics, during which time she led discovery and development programs to advance 15 compounds into clinical de...

Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....

read more...

read more...

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects....

Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline....

The stock has been on the rebound for several months, but can it keep the momentum going?...